Search research articles
Contact Us
Filters
Showing results (1-10 of 49) with videos related to
Page
of 5
Sort By:
CNS & Neurological Disorders Drug Targets
|
January 29, 2008
Cannabinoids and neuroprotection in motor-related disorders
Eva de Lago, Javier Fernández-Ruiz
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
January 17, 2018
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients
Francisco Espejo-Porras, Javier Fernández-Ruiz, Eva de Lago
Current Topics in Behavioral Neurosciences
|
July 24, 2025
Ageing, Neurodegeneration and the Endocannabinoid System
Javier Fernández-Ruiz, Onintza Sagredo, María Gómez-Ruiz, et al.
Biomolecules
|
September 23, 2022
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Isabel Lastres-Becker, Eva de Lago, Ana Martínez, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
March 11, 2025
Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays
María Gómez-Cañas, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, et al.
Expert Review of Clinical Pharmacology
|
November 25, 2011
Cannabinoids, multiple sclerosis and neuroprotection
Eva de Lago, María Gómez-Ruiz, Miguel Moreno-Martet, et al.
CNS Neuroscience & Therapeutics
|
April 8, 2014
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis
Miguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz, et al.
Expert Opinion on Therapeutic Targets
|
March 17, 2010
The endocannabinoid system as a target for the treatment of neuronal damage
Javier Fernández-Ruiz, Concepción García, Onintza Sagredo, et al.
Neuropharmacology
|
February 21, 2012
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
Eva de Lago, Miguel Moreno-Martet, Ana Cabranes, et al.
Brain Research
|
June 25, 2005
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
Eva de Lago, Paolo Urbani, José Antonio Ramos, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 49) with videos related to
Sort By:
Page
of 5
CNS & Neurological Disorders Drug Targets
|
January 29, 2008
Cannabinoids and neuroprotection in motor-related disorders
Eva de Lago, Javier Fernández-Ruiz
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
January 17, 2018
Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients
Francisco Espejo-Porras, Javier Fernández-Ruiz, Eva de Lago
Current Topics in Behavioral Neurosciences
|
July 24, 2025
Ageing, Neurodegeneration and the Endocannabinoid System
Javier Fernández-Ruiz, Onintza Sagredo, María Gómez-Ruiz, et al.
Biomolecules
|
September 23, 2022
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Isabel Lastres-Becker, Eva de Lago, Ana Martínez, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
March 11, 2025
Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays
María Gómez-Cañas, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, et al.
Expert Review of Clinical Pharmacology
|
November 25, 2011
Cannabinoids, multiple sclerosis and neuroprotection
Eva de Lago, María Gómez-Ruiz, Miguel Moreno-Martet, et al.
CNS Neuroscience & Therapeutics
|
April 8, 2014
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis
Miguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz, et al.
Expert Opinion on Therapeutic Targets
|
March 17, 2010
The endocannabinoid system as a target for the treatment of neuronal damage
Javier Fernández-Ruiz, Concepción García, Onintza Sagredo, et al.
Neuropharmacology
|
February 21, 2012
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
Eva de Lago, Miguel Moreno-Martet, Ana Cabranes, et al.
Brain Research
|
June 25, 2005
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
Eva de Lago, Paolo Urbani, José Antonio Ramos, et al.
Page
of 5